Although Pap smear screening has reduced cervical cancer incidence in the United States, cervical cancer continues to be associated with substantial morbidity and mortality, contributes to racial and ethnic disparities, and Imposes high economic costs. Advances in cancer epidemiology and medical technology provide a remarkable opportunity to improve upon the effectiveness and efficiency of the cervical cancer screening process. However, critical challenges remain with respect to clinical decision making and adoption of best practices, pertaining to patient behavior, provider incentives, health systems, and the real-world clinical effectiveness of emerging technologies. We propose to employ a decision-analytic approach, adapting an existing modeling framework by leveraging data from clinical provider networks and a state-of-the-art registry of cervical cancer Information in New Mexico;evaluate and weigh the tradeoffs (benefits and harms) of alternative cervical interventions across the continuum of care;explore the uncertainty around their outcomes;incorporate information on patient behavior and real-world practice;and inform timely clinical and policy questions. By achieving our specific aims, we expect to have an impact on (1) the effectiveness and efficiency of the cervical cancer screening process by investigating the effects of acceptability, delivery, and adoption of best practices;(2) cervical cancer outcomes, including reduced incidence, enhanced quality of life through earlier detection, improved survival, and reduced disparities;(3) the equitable distribution and rationale use of new technology;and (4) the financial and economic profile of health care organizations related to cervical cancer control.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center--Cooperative Agreements (U54)
Project #
5U54CA164336-03
Application #
8566821
Study Section
Special Emphasis Panel (ZCA1-SRLB-R)
Project Start
Project End
Budget Start
2013-06-01
Budget End
2014-05-31
Support Year
3
Fiscal Year
2013
Total Cost
$278,951
Indirect Cost
$63,125
Name
University of New Mexico Health Sciences Center
Department
Type
DUNS #
829868723
City
Albuquerque
State
NM
Country
United States
Zip Code
87131
Cuzick, Jack; Myers, Orrin; Hunt, William C et al. (2015) Human papillomavirus testing 2007-2012: co-testing and triage utilization and impact on subsequent clinical management. Int J Cancer 136:2854-63
Kim, Jane J (2014) Practice-based evidence for primary HPV testing in the United States. J Natl Cancer Inst 106:
Burger, Emily A; Sy, Stephen; Nygård, Mari et al. (2014) Prevention of HPV-related cancers in Norway: cost-effectiveness of expanding the HPV vaccination program to include pre-adolescent boys. PLoS One 9:e89974
Kinney, Walter; Hunt, William C; Dinkelspiel, Helen et al. (2014) Cervical excisional treatment of young women: a population-based study. Gynecol Oncol 132:628-35
Burger, Emily A; Kim, Jane J (2014) The value of improving failures within a cervical cancer screening program: an example from Norway. Int J Cancer 135:1931-9
Campos, Nicole G; Burger, Emily A; Sy, Stephen et al. (2014) An updated natural history model of cervical cancer: derivation of model parameters. Am J Epidemiol 180:545-55
Cuzick, Jack; Myers, Orrin; Hunt, William C et al. (2014) A population-based evaluation of cervical screening in the United States: 2008-2011. Cancer Epidemiol Biomarkers Prev 23:765-73
Wheeler, Cosette Marie (2013) The natural history of cervical human papillomavirus infections and cervical cancer: gaps in knowledge and future horizons. Obstet Gynecol Clin North Am 40:165-76
Kim, Jane J; Sharma, Monisha; Ortendahl, Jesse (2013) Optimal interval for routine cytologic screening in the United States. JAMA Intern Med 173:241-2
Bosch, F Xavier; Broker, Thomas R; Forman, David et al. (2013) Comprehensive control of human papillomavirus infections and related diseases. Vaccine 31 Suppl 8:I1-31